{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:30:04Z","timestamp":1792218604717,"version":"4.4.0"},"reference-count":82,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T00:00:00Z","timestamp":1427241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:p>Docetaxel (Taxotere<jats:sup>\u00ae<\/jats:sup>) has been one of the most important chemotherapeutic drugs for cancer treatment since 1996. Although a large number of clinical studies have been conducted in various cancer fields, there is a discrepancy in the standard dose between Japan and Western countries. This article reviews the pharmacokinetic, pharmacodynamic and toxicological profiles of docetaxel, and explains why there exists an ethnic difference in dose, and further discusses which direction we should go forward to solve this problem. The original recommended dose was 100\u00a0mg\/m<jats:sup>2<\/jats:sup> every 3\u00a0weeks in <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content> and European populations, while a Japanese phase\u00a0I study suggested the recommended dose as 60\u00a0mg\/m<jats:sup>2<\/jats:sup> every 3\u00a0weeks. A prospective population pharmacokinetic analysis of docetaxel conducted in both the <jats:styled-content style=\"fixed-case\">USA<\/jats:styled-content>\/Europe and Japan, indicated an absence of ethnic difference in the pharmacokinetics. Both analyses demonstrated that docetaxel clearance is related to \u03b11\u2010acid glycoprotein level, hepatic function, age and body surface area. The relationship was observed between increasing docetaxel dose and increased tumor response rates across the dose range of 60 to 100\u00a0mg\/m<jats:sup>2<\/jats:sup>. The area under the serum concentration time curve (<jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>) of docetaxel at the first cycle was significantly related to time to progression. Hematological toxicities were well correlated with the <jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content> of docetaxel, and severe hematological toxicities were more frequently observed in Japanese patients treated with 60\u00a0mg\/m<jats:sup>2<\/jats:sup>, compared to the <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content>\/European patients treated with 75\u2013100\u00a0mg\/m<jats:sup>2<\/jats:sup> dose. The Japanese population seems more susceptible to the toxicity of docetaxel. A docetaxel dose of 75\u00a0mg\/m<jats:sup>2<\/jats:sup> is now standard not only in global trials but also in recent Japanese trials. Although the optimal dose of docetaxel is still unclear, we need to continue to seek the appropriate dose of docetaxel depending on patient status and the goals of chemotherapy.<\/jats:p>","DOI":"10.1111\/cas.12647","type":"journal-article","created":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T06:38:51Z","timestamp":1424846331000},"page":"497-504","source":"Crossref","is-referenced-by-count":157,"title":["Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose"],"prefix":"10.1111","volume":"106","author":[{"given":"Hirotsugu","family":"Kenmotsu","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacokinetics and Pharmacodynamics Keio University School of Medicine Tokyo Japan"},{"name":"Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tanigawara","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics and Pharmacodynamics Keio University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,3,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.4.288"},{"key":"e_1_2_9_3_1","first-page":"1997","article-title":"Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug","volume":"21","author":"Taguchi T","year":"1994","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_2_9_4_1","first-page":"1037","article-title":"Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion","volume":"53","author":"Extra JM","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.5.950"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.11.2301"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050032"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.082"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00166.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936020-00002"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050799"},{"key":"e_1_2_9_12_1","first-page":"102","article-title":"Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony\u2010stimulating factor support in adult advanced solid tumors","volume":"9","author":"Goncalves A","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_13_1","first-page":"1077","article-title":"Alpha\u20101\u2010acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non\u2010small cell lung cancer treated with docetaxel","volume":"9","author":"Bruno R","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0842-03"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.187"},{"key":"e_1_2_9_16_1","first-page":"1255","article-title":"The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance","volume":"6","author":"Hirth J","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1636"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.036"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02353487"},{"key":"e_1_2_9_20_1","first-page":"479a","article-title":"Population pharmacokinetics of docetaxel in Japanese patients","volume":"15","author":"Tanigawara Y","year":"1996","journal-title":"ASCO Meeting Abstracts"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199810000-00004"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645030-00002"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00210785"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00222-4"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.09.005"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.01.001"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.12.026"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.18.3288"},{"key":"e_1_2_9_29_1","first-page":"2598","article-title":"Role of intestinal P\u2010glycoprotein in the plasma and fecal disposition of docetaxel in humans","volume":"6","author":"Zuylen L","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00035-7"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4230"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.025"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2649"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.60.5.934"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00765.x"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.02.003"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.95"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1872-4"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12186"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-422"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213480536"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100476"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.00992.x"},{"key":"e_1_2_9_44_1","first-page":"305","article-title":"Pharmacokinetics and metabolism of Taxotere (docetaxel)","volume":"17","author":"Bruno R","year":"1993","journal-title":"Cancer Surv"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1159\/000092903"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.163"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00611-1"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2345"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-011-0349-5"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500478"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1413"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.0294"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.027"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.10.2095"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2354"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.163"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602241"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.3739"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj115"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61758-4"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0185"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604372"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn705"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4146"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1903"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70132-7"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6491"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.6932"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70310-3"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4694"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70586-2"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010687017717"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1127"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603872"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-007-0232-0"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hym042"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.111948"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1628-6"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.20"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2011.10.002"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt236"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.12647","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12647","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.12647","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T01:18:29Z","timestamp":1696295909000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.12647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,25]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1111\/cas.12647"],"URL":"https:\/\/doi.org\/10.1111\/cas.12647","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,25]]}}}